ABCL Relative Valuation
ABCL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABCL is overvalued; if below, it's undervalued.
Historical Valuation
Abcellera Biologics Inc (ABCL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 10.71. The fair price of Abcellera Biologics Inc (ABCL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.57
Fair
-5.07
PE
1Y
3Y
5Y
Trailing
Forward
-2.94
EV/EBITDA
Abcellera Biologics Inc. (ABCL) has a current EV/EBITDA of -2.94. The 5-year average EV/EBITDA is 7.81. The thresholds are as follows: Strongly Undervalued below -105.19, Undervalued between -105.19 and -48.69, Fairly Valued between 64.31 and -48.69, Overvalued between 64.31 and 120.81, and Strongly Overvalued above 120.81. The current Forward EV/EBITDA of -2.94 falls within the Historic Trend Line -Fairly Valued range.
-2.79
EV/EBIT
Abcellera Biologics Inc. (ABCL) has a current EV/EBIT of -2.79. The 5-year average EV/EBIT is 17.40. The thresholds are as follows: Strongly Undervalued below -202.14, Undervalued between -202.14 and -92.37, Fairly Valued between 127.17 and -92.37, Overvalued between 127.17 and 236.94, and Strongly Overvalued above 236.94. The current Forward EV/EBIT of -2.79 falls within the Historic Trend Line -Fairly Valued range.
18.83
PS
Abcellera Biologics Inc. (ABCL) has a current PS of 18.83. The 5-year average PS is 29.93. The thresholds are as follows: Strongly Undervalued below -3.05, Undervalued between -3.05 and 13.44, Fairly Valued between 46.42 and 13.44, Overvalued between 46.42 and 62.91, and Strongly Overvalued above 62.91. The current Forward PS of 18.83 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Abcellera Biologics Inc. (ABCL) has a current P/OCF of 0.00. The 5-year average P/OCF is 13.64. The thresholds are as follows: Strongly Undervalued below -54.27, Undervalued between -54.27 and -20.31, Fairly Valued between 47.60 and -20.31, Overvalued between 47.60 and 81.56, and Strongly Overvalued above 81.56. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
5.62
P/FCF
Abcellera Biologics Inc. (ABCL) has a current P/FCF of 5.62. The 5-year average P/FCF is 11.41. The thresholds are as follows: Strongly Undervalued below -197.78, Undervalued between -197.78 and -93.19, Fairly Valued between 116.00 and -93.19, Overvalued between 116.00 and 220.60, and Strongly Overvalued above 220.60. The current Forward P/FCF of 5.62 falls within the Historic Trend Line -Fairly Valued range.
Abcellera Biologics Inc (ABCL) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of 1.23 , the current P/B ratio is approximately -11.66% higher. Relative to its 5-year average P/B ratio of 13.30, the current P/B ratio is about -91.86% higher. Abcellera Biologics Inc (ABCL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -10.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.59% , the current FCF yield is about -100.00% lower.
1.13
P/B
Median3y
1.23
Median5y
13.30
-14.66
FCF Yield
Median3y
-10.88
Median5y
-4.59
Competitors Valuation Multiple
The average P/S ratio for ABCL's competitors is 0.00, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 37.62%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABCL increased by 24.57% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.51M to 8.96M.
The secondary factor is the P/E Change, contributed 5.74%to the performance.
Overall, the performance of ABCL in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Abcellera Biologics Inc (ABCL) currently overvalued or undervalued?
What is Abcellera Biologics Inc (ABCL) fair value?
How does ABCL's valuation metrics compare to the industry average?
What is the current P/B ratio for Abcellera Biologics Inc (ABCL) as of Dec 05 2025?
What is the current FCF Yield for Abcellera Biologics Inc (ABCL) as of Dec 05 2025?
What is the current Forward P/E ratio for Abcellera Biologics Inc (ABCL) as of Dec 05 2025?